Clinical Intelligence/Clinical Efficiency

Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration

Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ: ARVN). This strategic partnership will involve Insilico Medicine’s AI-augmented platforms and close cooperation between Arvinas’ and Insilico Medicine’s scientists on novel PROTACs. The collaboration will include the design of transformative treatment modalities for existing and next-generation targets; and demonstrate the impact of combining AI with one of the most significant breakthrough technologies in drug discovery – PROTACs.

“Arvinas is the pioneer of PROTAC technology and a leader in protein degradation therapeutics. We look forward to collaborating with Arvinas in this innovative field and to building a lasting relationship,” said Alex Zhavoronkov Ph.D., CEO of Insilico Medicine.

In July the company announced the completion of a $255 million round led by Warburg Pincus and joined by over 25 high-profile investors, and in August,  it nominated the second preclinical candidate for kidney fibrosis.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to

Related posts

BERG Presents New Research on Potential Therapeutic Path

PR Newswire

Clinical Intelligence Company Caribou Biosciences Adds New Member

Business Wire

Med Tech Announces Business Intelligence for clinical Practices

PR Newswire